-transparent.png){kind=logo}
In cytotoxicity and indirect immunofluorescence tests an antiserum to ACA-1 (activated cell antigen) reacted with 58-100% of actively proliferating cells from tumors of lymphoid (EL-4 T lymphoma, MOPC 104E plasmacytoma) and nonlymphoid origin (AH-22 hepatoma, Sa-1 and MCh-11 sarcomas, F2 mammary cancer). Absorption of anti-ACA-1 serum with tumor cells sharply reduced its activity both against the cells of all these neoplasms and against normal activated T and B lymphocytes. Absorption with proliferating murine cells from the brain of embryos and the retina of neonates or with similar (nonproliferating) cells from adult mice did not affect the activity of the antiserum. It is concluded that ACA-1 is expressed on actively proliferating cells of the tumors studied.
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
July 1983,
Cellular immunology,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
January 1983,
Biulleten' eksperimental'noi biologii i meditsiny,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
July 1984,
Journal of immunology (Baltimore, Md. : 1950),
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
February 2023,
Human immunology,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
January 2017,
Cytotherapy,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
January 2013,
PloS one,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
July 1982,
Biulleten' eksperimental'noi biologii i meditsiny,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
July 1983,
Immunology,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
March 1994,
Blood,
V G Nesterenko, and
G P Yermakov, and
L N Fontalin, and
E I Rubakova
May 1996,
International immunology,
